Different Genes Influence Smoking Risk During Adolescence and Adulthood
Philadelphia, PA, 31 March, 2011 - There is growing evidence that the risk factors for addiction change throughout the lifespan.
The risk factors for developing addiction in adolescence are the most intensively studied because this life phase is associated with the highest addiction risk. Traits linked to addiction risk during adolescence include pleasure-seeking, behavioral disinhibition, and devaluation of the future negative consequences of behavior. In contrast, the development of substance use among adults is more commonly associated with high levels of stress, anxiety, and depression.
Thus, perhaps it is not surprising that different sets of genes are now implicated in the risk for addiction in adolescence and adulthood.
In a new study published in Biological Psychiatry, researchers found that teenagers carrying variants in two gene regions were three times more likely to become regular smokers in adolescence and twice as likely to be persistent smokers in adulthood, compared to non-carriers.
Variation in a set of dopamine-related genes was associated with a person's risk of starting smoking, and these genes had a stronger impact on smoking initiation in adolescents than in adults. Individuals carrying the risk variants had a 1.3-fold increased risk of starting smoking in their teenage years.
The other set of genes coded for subunits of the nicotinic cholinergic receptors, the brain targets for nicotine inhaled during smoking. Variation in these genes influenced the likelihood of smokers continuing the habit into adulthood, as it had a stronger influence on the smoking habits of adults than of adolescents. Those carrying these variants had a 1.3-fold increased risk of becoming a heavy and persistent smoker in adulthood.
“These findings seem to make some sense. The dopamine-related genes may be more closely associated with the risk for addiction within the context of thrill-seeking, while cholinergic receptors, which have been implicated in mood and cognition as well as addiction, might contribute toself-medication models of addiction,” commented Dr. John Krystal, Editor of Biological Psychiatry.
The researchers say the findings could help develop genetic testing for those wishing to know their susceptibility to nicotine dependence and tobacco-related disease. It could also pave the way for targeted drugs that influence an individual's response to nicotine. However, further research is necessary before these goals could be implemented.
# # #
Notes to Editors
The article is “TTC12-ANKK1-DRD2 and CHRNA5-CHRNA3-CHRNB4 Influence Different Pathways Leading to Smoking Behavior from Adolescence to Mid-Adulthood” by Francesca Ducci, Marika Kaakinen, Anneli Pouta, Anna-Liisa Hartikainen, Juha Veijola, Matti Isohanni, Pimphen Charoen, Lachlan Coin, Clive Hoggart, Jesper Ekelund, Leena Peltonen, Nelson Freimer, Paul Elliott, Gunter Schumann, and Marjo-Riitta Järvelin. The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.
The article appears in Biological Psychiatry, Volume 69, Number 7 (April 1, 2011), published by Elsevier.
John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological-Psychiatry-Editorial-Disclosures-7-22-10.pdf.
Full text of the article mentioned above is available upon request. Contact Chris J. Pfister at email@example.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length reports of novel results, commentaries, case studies of unusual significance, and correspondence judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise reviews and editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry ( www.sobp.org/journal) is ranked 4th out of 117 Psychiatry titles and 13th out of 230 Neurosciences titles in the 2009 ISI Journal Citations Reports® published by Thomson Reuters. The 2009 Impact Factor score for Biological Psychiatry has increased to 8.926.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
Chris J. Pfister
Strategic Marketing Manager - Elsevier